Navigation Links
Experimental Drug May Prevent Plaque Buildup
Date:2/20/2009

Further study, though, could reveal pitfalls, expert warns

FRIDAY, Feb. 20 (HealthDay News) -- An experimental drug called A-002 appears effective in preventing atherosclerosis, according to a phase II study that included American and Ukrainian participants.

In atherosclerosis, arteries become blocked and inflamed by a buildup of white blood cells and fatty material, or lipids. Two potentially bioactive fats that can be involved in atherosclerosis are produced when enzymes known as sPLA2 break down particular molecules in the blood and artery walls. The drug A-002 targets three groups of these enzymes that are present in high levels in atherosclerotic lesions.

The 393 people in the study were randomly selected to receive one of four doses of the drug (50, 100, 250 or 500 milligrams) or a placebo twice a day for eight weeks.

Among people taking any dose of A-002, average enzyme levels decreased by 87 percent, compared with a 5 percent drop in the placebo group. The reduction varied by dosage, ranging from an average of 69 percent for those taking 50 mg to 96 percent for people taking 500 mg.

Average levels of low-density lipoprotein cholesterol (the bad type) decreased by 8 percent among people given A-002, compared with a 1.7 percent decline in the placebo group. Concentrations of the inflammatory marker C-reactive protein fell by 56 percent among people taking the drug and 25 percent among those given the placebo.

The findings appear in this week's issue of The Lancet.

"Our study demonstrates that sPLA2 inhibition produces favorable changes in plasma lipids, oxidized LDL and inflammatory markers, and the magnitude of these changes was larger in statin-treated patients," Dr. Robert S. Rosenson, a specialist in cardiovascular medicine at the University of Michigan Medical School, and colleagues wrote.

Though Rosenson said that further study is needed to determine "the effects of sPLA2 inhibition on reducing atherosclerosis progression and cardiovascular events," the study's conclusion suggested that "the reductions in sPLA2 concentration suggest that A-002 might be an effective anti-atherosclerotic agent."

In an accompanying editorial in The Lancet, Dr. Marshall A. Corson, of the University of Washington/Harborview Medical Center in Seattle, noted that a number of other seemingly promising anti-inflammatory or antioxidant therapies eventually proved ineffective or harmful.

This "suggests that challenges might lie ahead for sPLA2 inhibitors," Corson wrote. "These difficulties could increase the regulatory hurdles that need to be cleared for these, or other, novel anti-atherosclerotic therapies."

More information

The U.S. National Heart, Lung, and Blood Institute has more about atherosclerosis.



-- Robert Preidt



The Lancet, news release, Feb. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug May Prevent Plaque Buildup
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A ... their parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” ... Long Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael ...
(Date:8/18/2017)... Lynchburg, VA (PRWEB) , ... August 18, 2017 , ... ... to the Democratic Republic of Congo (DRC) thanks to an ambitious venture that conjoined ... as well as the generous support of the Liberty community. These shoes will save ...
(Date:8/18/2017)... York (PRWEB) , ... August ... ... LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider ... has entered into a definitive agreement to purchase Unitrans International Corporation, a ...
(Date:8/18/2017)... New York, NY (PRWEB) , ... August 18, ... ... the launch of this summer’s edition of “Vision & Hearing,” advocating for active, ... The campaign focuses on resources available for individuals with hearing impairments and shares ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... 2017  Opioid addiction and other drugs of abuse, ... and threatening outcomes, were problems taken on directly as ... that support them, met this week. This according to ... drugs of abuse, procalcitonin and acute kidney injury were ... 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... -- Life Flight Network and PeaceHealth Oregon Network announced they renewed ... operational efficiency for patients at hospitals in Eugene ... Grove , and Florence, Oregon , ... Network work collaboratively to move patients who require the highest ... sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
Breaking Medicine Technology: